— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., J
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
